Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Background: The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most common health care–associated IFI. We evaluated the activity of fluconazole (FLU) against 20 788 invasive isolates of Candida (37 species) collected from 135 medical centers in 39 countries (1997–2016). The activity of anidulafungin, caspofungin, and micafungin (MCF) was evaluated against 15 308 isolates worldwide (2006–2016). Methods: Species identification was accomplished using phenotypic (1997–2001), genotypic, and proteomic methods (2006–2016). All isolates were tested using reference methods and clinical breakpoints published in the Clinical and Laboratory Standards Institute documents. Results: A decrease in the isolation of Candida albicans and an increase in the isolation of Candida glabrata and Candida parapsilosis were observed over time. Candida glabrata was the most common non–C. albicans species detected in all geographic regions except for Latin America, where C. parapsilosis and Candida tropicalis were more common. Six Candida auris isolates were detected: 1 each in 2009, 2013, 2014, and 2015 and 2 in 2016; all were from nosocomial bloodstream infections and were FLU-resistant (R). The highest rates of FLU-R isolates were seen in C. glabrata from North America (NA; 10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%). A steady increase in isolation of C. glabrata and resistance to FLU was detected over 20 years in the United States. Echinocandin-R (EC-R) ranged from 3.5% for C. glabrata to 0.1% for C. albicans and C. parapsilosis. Resistance to MCF was highest among C. glabrata (2.8%) and C. tropicalis (1.3%) from NA. Mutations on FKS hot spot (HS) regions were detected among 70 EC-R isolates (51/70 were C. glabrata). Most isolates harboring FKS HS mutations were resistant to 2 or more ECs. Conclusions: EC-R and FLU-R remain uncommon among contemporary Candida isolates; however, a slow and steady emergence of resistance to both antifungal classes was observed in C. glabrata and C. tropicalis isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although relatively low levels of resistance for most Candida species have been described, the outcomes for candidemia remain poor, as high levels of mortality (15%-50%) have been associated with candida infections7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this Review, we explore the molecular mechanisms that contribute to antifungal drug resistance, with a focus on Candida spp., the most common cause of fungal infections in humans7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measured
22 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“Sentinel surveillance programs designed to capture organisms and patient demographic data from representative sites spanning a larger geographical area and over a longer period of time serve to fill the gaps in time and space that are necessarily left by the more intensive and focused, yet intermittent, population-bas…”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12]; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs.”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 2×
“S90 • OFID 2019:6 (Suppl 1) • Pfaller et al SENTRY Program Candida Surveillance (1997–2016) • OFID 2019:6 (Suppl 1) • S91 [93, 94], and emerging resistance mechanisms [20, 68] highlight the importance of local and global surveillance studies.”
BackgroundSelf-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Caspofungin, micafungin, and anidulafungin were approved for clinical use by the US Food and Drug Administration (FDA) in 2001, 2005, and 2006, respectively, and are now recommended as firstline agents for treating IC [50, 67].”
BackgroundCalderone, R. (2012) · ASM Press eBooks · Cited by 912
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citation
Research works printed but not linked: 4
- 38. CLSI. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- 39. CLSI. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
- 40. CLSI. M59. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- 63. Pfaller MA, Diekema DJ Azole antifungal drug cross-resistance: mechanisms epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1: 74– 92.
Cited by
Items 201–300 of 931
Lu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
N-Acetylglucosamine (GlcNAc) Sensing, Utilization, and Functions in Candida albicans
Du, H., Ennis, C. L., Hernday, A. D., Nobile, C. J., & Huang, G. (2020) · Journal of Fungi · doi:10.3390/jof6030129 · Cited by 30
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
Susan, V., Lang, M., Sabou, M., & Bourel‐Bonnet, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081220 · Cited by 30
Small molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates
Alabi, P., Gautier, C., Murphy, T. P., Gu, X., Lepas, M., Aimanianda, V., Sello, J. K., & Ene, I. V. (2023) · mBio · doi:10.1128/mbio.00479-23 · Cited by 30
Scott, N. E., Erayil, S. E., Kline, S. E., & Selmecki, A. M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-23 · Cited by 30
Locke, J. B., Pillar, C. M., Castanheira, M., Carvalhaes, C. G., Andes, D. R., Aram, J. A., Andrzejewski, C., Bartizal, K. F., Das, A., Sandison, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-23 · Cited by 31
Self-citationHernández-Pabón, J. C., Tabares, B., Gil, Ó., Lugo-Sánchez, C., Santana, A., Barón, A., & Firacative, C. (2024) · Journal of Fungi · doi:10.3390/jof10050326 · Cited by 30
Kajihara, T., Yahara, K., Nagi, M., Kitamura, N., Hirabayashi, A., Hosaka, Y., Abe, M., Miyazaki, Y., & Sugai, M. (2022) · Medical Mycology · doi:10.1093/mmy/myac071 · Cited by 29
Candidemia in Children: A 16-year Longitudinal Epidemiologic Study
Silvester, E. J., Watanabe, M., Pittet, L. F., Boast, A., Bryant, P. A., Haeusler, G. M., Daley, A. J., Curtis, N. C., & Gwee, A. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003082 · Cited by 29
Pfaller, M. A., Carvalhaes, C. G., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00431-4 · Cited by 29
Self-citationDíaz-García, J., Mesquida, A., Gómez, A., Machado, M., Martín‐Rabadán, P., Alcalá, L., Sánchez‐Carrillo, C., Reigadas, E., Vicente, T., Muñoz, P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01249-21 · Cited by 29
Ashkenazi‐Hoffnung, L., & Danziger, C. R. (2023) · Journal of Fungi · doi:10.3390/jof9020176 · Cited by 29
Candida parapsilosis Sensu Stricto Antifungal Resistance Mechanisms and Associated Epidemiology
Franconi, I., Rizzato, C., Poma, N. V., Tavanti, A., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9080798 · Cited by 29
MixInYeast: A Multicenter Study on Mixed Yeast Infections
Medina, N., Soto-Debrán, J. C., Seidel, D., Akyar, I., Badali, H., Barac, A. M., Bretagne, S., Çağ, Y., Cassagne, C., Castro, C., et al. (2020) · Journal of Fungi · doi:10.3390/jof7010013 · Cited by 29
Meyahnwi, D., Siraw, B. B., & Reingold, A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07848-8 · Cited by 28
Is Natural Population of Candida tropicalis Sexual, Parasexual, and/or Asexual?
Xu, J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.751676 · Cited by 28
COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Domán, M., & Bànyai, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919501 · Cited by 29
Satała, D., Juszczak, M., Wronowska, E., Surowiec, M., Kulig, K., Kozik, A., Rąpała‐Kozik, M., & Karkowska‐Kuleta, J. (2022) · Cellular Microbiology · doi:10.1155/2022/2599136 · Cited by 28
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Flanagan, S., Walker, H., Ong, V. S., & Sandison, T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01339-23 · Cited by 28
Roepcke, S., Passarell, J. A., Walker, H., & Flanagan, S. D. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00916-23 · Cited by 28
Avramovska, O., & Hickman, M. A. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400752 · Cited by 29
Development of Thiazolidinones as Fungal Carbonic Anhydrase Inhibitors
Güzel-Akdemir, Ö., Carradori, S., Grande, R., Demir-Yazıcı, K., Angeli, A., Supuran, C. T., & Akdemir, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082960 · Cited by 28
Gale, A. N., Pavesic, M. W., Nickels, T. J., Xu, Z., Cormack, B. P., & Cunningham, K. W. (2023) · mSphere · doi:10.1128/msphere.00254-23 · Cited by 27
Camaioni, L., Ustyanowski, B., Buisine, M., Lambert, D., Sendid, B., Billamboz, M., & Jawhara, S. (2023) · Antibiotics · doi:10.3390/antibiotics12111603 · Cited by 27
Khalifa, H. O., Hubka, V., Watanabe, A., Nagi, M., Miyazaki, Y., Yaguchi, T., & Kamei, K. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01856-21 · Cited by 27
Ye, N., Liu, Z., Tang, W. F., Li, X., Chu, W., & Zhou, Q. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s378629 · Cited by 27
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 27
Self-citationVena, A., Tiseo, G., Falcone, M., Bartalucci, C., Marelli, C., Cesaretti, M., Pilato, V. D., Escribano, P., Forniti, A., Giacobbe, D. R., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae603 · Cited by 28
Williams, C. C., Gregory, J., & Usher, J. (2024) · Microbiology · doi:10.1099/mic.0.001512 · Cited by 27
Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?
Novak, A. R., Bradley, M. E., Kiser, T. H., & Mueller, S. W. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00379-2 · Cited by 26
Correia, I., Wilson, D., Hube, B., & Plá, J. (2020) · Journal of Fungi · doi:10.3390/jof6040230 · Cited by 26
Szekely, J., Rakchang, W., Rattanaphan, P., & Kositpantawong, N. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823001346 · Cited by 26
Progress in the application of nanoparticles for the treatment of fungal infections: A review
Zhu, X., Chen, Y.-M., Yu, D. B., Fang, W., Liao, W., & Pan, W. (2023) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2023.2285764 · Cited by 27
Misas, E., Seagle, E. E., Jenkins, E. N., Rajeev, M., Hurst, S. F., Nunnally, N. S., Bentz, M. L., Lyman, M., Berkow, E. L., Harrison, L. H., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-23 · Cited by 26
Zhang, L., Yu, S.-Y., Chen, S. C.-A., Xiao, M., Kong, F., Wang, H., Ning, Y., Lu, M., Sun, T., Hou, X., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01320 · Cited by 26
Dumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., et al. (2023) · eLife · doi:10.7554/elife.81406 · Cited by 25
Katsiari, M., Mavroidi, A., Kesesidis, N., Palla, E., Zourla, K., Ntorlis, K., Konstantinidis, K., Laskou, M., Konstantinos, S., Sakkalis, A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020243 · Cited by 25
Optimizing the Treatment of Invasive Candidiasis—A Case for Combination Therapy
Wake, R. M., Allebone-Salt, P. E., John, L. L. H., Caswall, B. A., Govender, N. P., Ben‐Ami, R., Murray, L., Logan, C., Harrison, T. S., & Bicanic, T. A. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae072 · Cited by 26
Meneghello, S., Bernabé, G., Pietra, G. D., Sopra, S. D., Vecchio, C. D., Cattelan, A. M., Castagliuolo, I., & Brun, P. (2024) · Journal of Fungi · doi:10.3390/jof10100707 · Cited by 25
Guo, L., Yu, S.-Y., Xiao, M., Yang, C.-X., Bao, C., Yu, Y., Ye, L., Yang, Y., Zhang, G., Liu, J., et al. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s255843 · Cited by 25
Demin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Candida auris: The Canary in the Mine of Antifungal Drug Resistance
Montoya, M. C., Moye-Rowley, W. S., & Krysan, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00239 · Cited by 21
Bergin, S. A., Doorley, L. A., Rybak, J. M., Wolfe, K. H., Butler, G., Cuomo, C. A., & Rogers, P. D. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01619-23 · Cited by 24
Won, E. J., Choi, M. J., Jeong, S. H., Kim, D., Shin, K. S., Shin, J. H., Kim, Y. R., Kim, H. S., Kim, Y. A., Uh, Y., et al. (2022) · Journal of Fungi · doi:10.3390/jof8100996 · Cited by 24
Bilal, H., Zhang, D., Shafiq, M., Khan, M. N., Chen, C., Khan, S., Wang, Q., Cai, L., Islam, R., Hu, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00708-23 · Cited by 24
Kioshima, É. S., Mesquita, C. S. S., Abadio, A. K. R., Felipe, M. S. S., Svidzinski, T. I. E., & Maigret, B. (2019) · Biotechnology Letters · doi:10.1007/s10529-019-02747-6 · Cited by 24
Kim, T. Y., Huh, H. J., Lee, G. Y., Choi, M. J., Yu, H., Cho, S. Y., Chang, Y. S., Kim, Y., Shin, J. H., & Lee, N. Y. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00889-22 · Cited by 24
Approaches for identifying and measuring heteroresistance in azole-susceptible Candida isolates
Gautier, C., Maciel, E. I., & Ene, I. V. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04041-23 · Cited by 23
Histone Acetylation Regulator Gcn5 Mediates Drug Resistance and Virulence of Candida glabrata
Yu, S., Paderu, P., Lee, A., Eirekat, S., Healey, K., Chen, L., Perlin, D. S., & Zhao, Y. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00963-22 · Cited by 23
“albicans Candida species have increased significantly in the past 2 decades (3, 4), among which Candida glabrata is the most frequently isolated species in the SENTRY antifungal surveillance program (5).”
BackgroundCandida glabrata: A Tale of Stealth and Endurance
Askari, F., & Kaur, R. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00477 · Cited by 24
Spiliopoulou, A., Kolonitsiou, F., Vrioni, G., Tsoupra, S., Lekkou, A., & Paliogianni, F. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101236 · Cited by 23
Holzknecht, J., Dubrac, S., Hedtrich, S., Galgóczy, L., & Marx, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00299-22 · Cited by 23
Wu, H.-N., Yuan, E.-Y., Li, W., Peng, M., Zhang, Q.-Y., & Xie, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.876207 · Cited by 23
Sathi, F. A., Paul, S. K., Ahmed, S., Alam, M. M., Nasreen, S. A., Haque, N., Islam, A., Nila, S. S., Afrin, S. Z., Aung, M. S., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7090211 · Cited by 23
Candida endocarditis: Update on management considerations
Jamil, Y., Akinleye, A. A., Mirzaei, M., Lempel, M., Farhat, K., & Pan, S. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i10.469 · Cited by 23
Elalouf, A., Elalouf, H., & Rosenfeld, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292625 · Cited by 24
Aldejohann, A. M., Menner, C., Thielemann, N., Martin, R., Walther, G., & Kurzai, O. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-23 · Cited by 23
Zhou, X., Hilk, A. L., Solis, N. V., Scott, N. E., Beach, A., Soisangwan, N., Billings, C. L., Burrack, L. S., Filler, S. G., & Selmecki, A. M. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01795-7 · Cited by 23
Global Secretome Characterization of the Pathogenic Yeast Candida glabrata
Rasheed, M., Kumar, N., & Kaur, R. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00299 · Cited by 23
Candidemia in Internal Medicine: Facing the New Challenge
Brescini, L., Mazzanti, S., Morroni, G., Pallotta, F., Masucci, A., Orsetti, E., Montalti, R., & Barchiesi, F. (2022) · Mycopathologia · doi:10.1007/s11046-022-00624-x · Cited by 23
Zajac, C., Scott, N. E., Kline, S., Erayil, S. E., & Selmecki, A. M. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00102-6 · Cited by 22
Tan, C., Wu, A., & Li, C. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102947 · Cited by 22
Hernando-Ortiz, A., Mateo, E., Ortega-Riveros, M., De-la-Pinta, I., Quindós, G., & Eraso, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00824-20 · Cited by 22
Pietrobom, P. M. P., & Colombo, A. L. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000684 · Cited by 22
Pfaller, M. A., Carvalhaes, C. G., DeVries, S. D., Huband, M. D., & Castanheira, M. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115627 · Cited by 22
Self-citationKumar, K., Moirangthem, R., & Kaur, R. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008620 · Cited by 22
Siswina, T., Rustama, M. M., Sumiarsa, D., & Kurnia, D. (2023) · F1000Research · doi:10.12688/f1000research.125645.3 · Cited by 21
Schaefer, S., Melodia, D., Pracey, C. P., Corrigan, N. A., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01038 · Cited by 21
Puumala, E., Nandakumar, M., Yiu, B., Stogios, P. J., Strickland, B. G., Żarnowski, R., Wang, X., Williams, N. S., Savchenko, A. V., Andes, D. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57346-z · Cited by 21
Antimycotic Drugs and their Mechanisms of Resistance to Candida Species
Dahiya, S., Sharma, N., Punia, A., Choudhary, P., Gulia, P., Parmar, V. S., & Chhillar, A. K. (2021) · Current Drug Targets · doi:10.2174/1389450122666210719124143 · Cited by 22
Hao, W., Wang, Y., Xi, Y., Yang, Z., Zhang, H., & Ge, X. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.09.018 · Cited by 21
Pandey, N., Gupta, M. K., Paul, P., & Tilak, R. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.12.002 · Cited by 21
Moirangthem, R., Kumar, K., & Kaur, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02415-20 · Cited by 20
Wang, Q., Cai, X., Li, Y., Zhao, J., Liu, Z., Jiang, Y., Ling, M., Li, Y., Pan, S., Ai, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1006375 · Cited by 20
Spruijtenburg, B., Rudramurthy, S. M., Meijer, E. F. J., van Haren, M. H. I., Kaur, H., Chakrabarti, A., Meis, J. F. G. M., & de Groot, T. (2023) · Microorganisms · doi:10.3390/microorganisms11061525 · Cited by 20
Zhou, X., Hilk, A. L., Solis, N. V., de Sá, N. P., Hogan, B. M., Bierbaum, T. A., Poeta, M. D., Filler, S. G., Burrack, L. S., & Selmecki, A. M. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012389 · Cited by 20
Antimicrobial Activity of Silver Camphorimine Complexes against Candida Strains
Costa, J. P., Pinheiro, M. J. F., Sousa, S. A., do Rego, A. M. B., Marques, F., Oliveira, M. C., Leitão, J. H., Mira, N. P., & Carvalho, M. F. N. N. (2019) · Antibiotics · doi:10.3390/antibiotics8030144 · Cited by 20
Origin of new emergent Coronavirus and Candida fungal diseases—Terrestrial or cosmic?
Steele, E. J., Gorczynski, R. M., Lindley, R. A., Tokoro, G., Temple, R., & Wickramasinghe, N. C. (2020) · Advances in genetics · doi:10.1016/bs.adgen.2020.04.002 · Cited by 20
Bairwa, G., Sánchez‐León, E., Do, E., Jung, W. H., & Kronstad, J. W. (2020) · mBio · doi:10.1128/mbio.00986-20 · Cited by 20
The yapsin family of aspartyl proteases regulate glucose homeostasis in Candida glabrata
Askari, F., Rasheed, M., & Kaur, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101593 · Cited by 20
Salazar, S. B., Pinheiro, M. J. F., Sotti-Novais, D., Soares, A. R., Lopes, M. M., Ferreira, T., Rodrigues, V., Fernandes, F., & Mira, N. P. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac110 · Cited by 20
Dougue, A. N., El‐Kholy, M. A., Giuffrè, L., Galeano, G., D′Aleo, F., Kountchou, C. L., Nangwat, C., Dzoyem, J. P., Giosa, D., Pernice, I., et al. (2022) · Mycoses · doi:10.1111/myc.13483 · Cited by 20
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 20
An Association of an eBURST Group With Triazole Resistance of Candida tropicalis Blood Isolates
Tulyaprawat, O., Pharkjaksu, S., Chongtrakool, P., & Ngamskulrungroj, P. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00934 · Cited by 20
Lim, H. J., Shin, J. H., Kim, M., Yong, D., Byun, S. A., Choi, M. J., Lee, S. Y., Won, E. J., Kee, S., Kim, S. H., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00740-20 · Cited by 20
Garbez, N., Mbatchi, L., Wallis, S. C., Müller, L., Lipman, J., Roberts, J. A., Lefrant, J., & Roger, C. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02307-20 · Cited by 19
Epidemiological patterns of candidaemia: A comprehensive analysis over a decade
Ferngren, G., Yu, D. C., Ünalan-Altıntop, T., Dinnétz, P., & Özenci, V. (2024) · Mycoses · doi:10.1111/myc.13729 · Cited by 19
Hamburger, F. G., Gales, A. C., & Colombo, A. L. (2024) · Mycopathologia · doi:10.1007/s11046-024-00867-w · Cited by 19
Binder, U., Arastehfar, A. A., Schnegg, L., Hörtnagl, C., Polat, S. H., Perlin, D. S., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040377 · Cited by 19
Clinical utility of antifungal susceptibility testing
McCarty, T. P., Luethy, P. M., Baddley, J. W., & Pappas, P. G. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac067 · Cited by 19
Pais, P., Galocha, M., Takahashi‐Nakaguchi, A., Chibana, H., & Teixeira, M. C. (2022) · Microbial Cell · doi:10.15698/mic2022.11.786 · Cited by 19
Lim, H. J., Choi, M. J., Byun, S. A., Won, E. J., Park, J.-H., Choi, Y. J., Choi, H., Choi, H.-W., Kee, S., Kim, S. H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050515 · Cited by 19
Bretagne, S., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Che, D., Dromer, F., & YEASTS, P. O. T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641965 · Cited by 19
Lee, Y., Liston, S. D., Lee, D., Robbins, N., & Cowen, L. E. (2022) · iScience · doi:10.1016/j.isci.2022.104432 · Cited by 18
Francisco, E. C., Cáceres, D. H., Brunelli, J. G. P., García‐Effrón, G., Arastehfar, A. A., Ribeiro, F. D. C., Almeida, M. N. D., Gonçalves, S. S., de Almeida, J. N., Lass‐Flörl, C., et al. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-23 · Cited by 18
Abbaoui, Z., Khibech, O., Oulous, A., Karcı, H., Dündar, M., Özdemir, İ., Gürbüz, N., Koç, A., Özdemır, İ., & Touzani, R. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00445-y · Cited by 18
Lewis, R. E., & Andes, D. R. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000740 · Cited by 18
Silva, L. C., Correia, A. F., Gomes, J. V. D., Romão, W., Motta, L. C., Fagg, C. W., Magalhães, P. O., Silveira, D., & Fonseca-Bazzo, Y. M. (2022) · Molecules · doi:10.3390/molecules27092976 · Cited by 18
Rodrigues, D. S., Cabral, V. P. D. F., Barbosa, A. D., Sá, L. G. D. A. V., Moreira, L. E. A., Neto, J. B. D. A., da Silva, C. R., de Moraes, M. O., Silva, J., Marinho, E. S., et al. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001664 · Cited by 18
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N.
- Affiliations
- University of Iowa (US)
- The University of Adelaide (AU)
- JMI Laboratories (US)
- Corresponding author
- Pfaller, Michael A
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03
- Volume
- 6
- Issue
- Supplement_1
- Pages
- S79-S94
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC6419901
- OpenAlex
- W2922388167
- Semantic Scholar
- b99f36f4463b9afe6d2a0ab52eebb3f5e726f4c0
- Cited by
- 825
- References
- 114
- Citations by year
- 2026: 92 · 2025: 129 · 2024: 133 · 2023: 141 · 2022: 94 · 2021: 108 · 2020: 104 · 2019: 24
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- JMI Laboratories
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- invasive candidiasis, Candida species, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida auris, micafungin resistance, caspofungin, anidulafungin, Candida species distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.